Capricor Therapeutics Class Action Lawsuit: Investors with Losses Have Leading Role

Capricor Therapeutics Class Action Lawsuit Overview

Investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) have a crucial opportunity to take action after facing considerable financial losses. Robbins Geller Rudman & Dowd LLP has announced that individuals who purchased Capricor securities between December 17, 2025, and July 26, 2026, can seek to be appointed as the lead plaintiff in a class action lawsuit against the company.

Allegations Against Capricor

The lawsuit, filed in the Southern District of California, alleges that Capricor and certain top executives violated provisions of the Securities Exchange Act of 1934. Specifically, the claims center around the company’s product candidate, Deramiocel, which targets Duchenne muscular dystrophy, a severe genetic disorder that leads to muscle degeneration. Capricor’s lead product is intended to address complications related to this condition.

The class action alleges that throughout the stated period, the defendants made false or misleading statements regarding the clinical trial results for Deramiocel, failing to disclose significant changes made to the statistical analysis plan that had not been approved by the FDA. The lawsuit asserts that the FDA had not agreed to these changes prior to the resubmission of the Biologics License Application (BLA) for Deramiocel, which unleashed a wave of risks concerning the product's potential approval.

Events That Triggered Market Response

On July 27, 2026, before the market opened, the FDA released briefing documents revealing concerns with Capricor's statistical analysis plans. The documents indicated that the analyses presented by Capricor were deemed complex and lacking scientific justification, thus raising doubts about the effectiveness of Deramiocel. Following the release of this information, shares of Capricor plummeted significantly, experiencing a 64% drop in price.

Furthermore, on July 29, 2026, an advisory committee meeting took place, ultimately leading to a recommendation against Deramiocel’s efficacy for treating DMD-associated cardiomyopathy. As a result, the stock price fell another 36% in the aftermath of this meeting.

The Role of the Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who suffered losses during the class period has the right to seek the role of lead plaintiff. This individual typically has the largest financial stake in the case and acts on behalf of all other affected investors. The lead plaintiff has the authority to select a law firm to represent the class in court. Importantly, an investor’s ability to benefit from any potential recovery does not depend on their designation as lead plaintiff.

How to Participate

Interested investors can either submit their information through the firm's website or contact attorneys directly. Individuals wishing to take part in the lawsuit or who have questions about their eligibility should consider reaching out to Robbins Geller Rudman & Dowd LLP via phone or email for further guidance.

While navigating through the complexities of securities fraud and shareholder rights can be daunting, firms like Robbins Geller provide a wealth of experience and resources to assist investors. Their extensive history in securities class action cases offers hope for potential restitution.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP has solidified its status as a leading law firm representing investors in securities fraud cases. They recently ranked first for the recovery of settlements for investors, emphasizing their commitment to shareholder activism and rights. With an impressive track record of recovering billions for clients, the firm plays a crucial role in the financial landscape for those pursuing justice and compensation.

Investors in Capricor Therapeutics facing significant losses must act swiftly, as the deadline to apply for lead plaintiff status is September 28, 2026. For additional details and guidance, visit the law firm’s dedicated resources or contact them directly.